Fatality rate for men with breast cancer has soared compared to women
Researchers say there are a number of factors behind the disparity, but stress that more research into differences in treatment and awareness is needed.
Related Articles
With a win in lung cancer, biotech’s wealthiest outsider surfs to new heights
Summit’s lung cancer treatment has wowed researchers. The CEO behind it is a living challenge to the assumptions of many in biotech.
BMS immunotherapy improves responses in lung cancer, setting up Phase 3 study
Using a second BMS immunotherapy added to the benefits for certain patients with non-small cell lung cancer.
Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising response rates in patients with a type of…
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
Here are some highlights of the 2024 ESMO conference in Barcelona.
Inquiry into unexplained bird flu case in Missouri broadens to a close contact
Mystery H5 flu case had a close contact who was ill at same time; CDC hopes blood tests will show if there was a connection.
Get your first 3 months of STAT+ for $5
Subscribe to STAT+ and stay up-to-date on the latest trends and ground breaking discoveries in cancer research.
What does the presidential election mean for ICHRA and the health insurance market?
Either Harris or Trump could enact changes to the health insurance market that bump HRAs off their path to growth.
Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
Anthem Blue Cross Blue Shield is taking an unusually hard line on doctors who it says improperly prescribed Ozempic.
FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has its own injectable…